CoChat

CA 19-9: Biochemical and Clinical Aspects

Scarà, Salvatore, Bottoni, Patrizia, Scatena, Roberto · 2015 · Advances in Experimental Medicine and Biology

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.

Abstract

CA19-9 (carbohydrate antigen 19-9, also called cancer antigen 19-9 or sialylated Lewis a antigen) is the most commonly used and best validated serum tumor marker for pancreatic cancer diagnosis in symptomatic patients and for monitoring therapy in patients with pancreatic adenocarcinoma. Normally synthesized by normal human pancreatic and biliary ductal cells and by gastric, colon, endometrial and salivary epithelia, CA 19-9 is present in small amounts in serum, and can be over expressed in several benign gastrointestinal disorders. Importantly, it exhibits a dramatic increase in its plasmatic levels during neoplastic disease. However, several critical aspects for its clinical use, such as false negative results in subjects with Lewis (a-b-) genotype and false positive elevation, occasional and transient, in patients with benign diseases, together with its poor positive predictive value (72.3 %), do not make it a good cancer-specific marker and renders it impotent as a screening tool. In the last years a large number of putative biomarkers for pancreatic cancer have been proposed, most of which is lacking of large scale validation. In addition, none of these has showed to possess the requisite sensitivity/specificity to be introduced in clinical use. Therefore, although with important limitations we well-know, CA 19-9 continues being the only pancreatic cancer marker actually in clinical use.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-94-017-7215-0_15

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 84 references

Research works printed but not linked: 4

  1. Hakomori S, Kannagi R (1983) Glycosphyngolipids as tumor-associated and differentiation markers. J Natl Cancer Inst (Bethesda) 71:231–251
  2. Frebourg T, Bercoff E, Manchon N et al (1988) The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 62:2287–2290 · doi:10.1002/1097-0142(19881201)62:11<2287::aid-cncr2820621103>3.0.co;2-h
  3. National Health Insurance Corporation (2000) National health insurance statistical yearbook 1999, 21:350–563
  4. Sturgeon C, Dati F, Duffy MJ et al (1999) Quality requirements and control: EGTM recommendations. Anticancer Res 19:2785–2820

Cited by

See all 374

Metadata

Authors
Scarà, S., Bottoni, P., & Scatena, R.
Affiliations
Università Cattolica del Sacro Cuore (IT)
Corresponding author
Bottoni, Patrizia
Venue
Advances in Experimental Medicine and Biology
Published
2015
Volume
867
Pages
247-260
ISSN
  • 0065-2598 (ISSN-L)
  • 2214-8019
OpenAlex
W2184169423
Cited by
351
References
83
Citations by year
2026: 33 · 2025: 46 · 2024: 51 · 2023: 40 · 2022: 48 · 2021: 39 · 2020: 29 · 2019: 26 · 2018: 21 · 2017: 11 · 2016: 6
FWCI
25.12
Type
book chapter
Language
en
Open access
closed
Licence
Locations
  • Advances in experimental medicine and biology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
CA19-9, pancreatic cancer, serum tumor markers, pancreatic ductal adenocarcinoma, cancer screening, false-negative results, benign gastrointestinal disease, biomarkers, treatment monitoring
MeSH terms
Humans, Pancreatic Neoplasms, Sensitivity and Specificity, CA-19-9 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CA 19-9: Biochemical and Clinical Aspects. https://app.cochat.ai/papers/10.1007/978-94-017-7215-0_15
The paper
Scarà, S., Bottoni, P., & Scatena, R. (2015). CA 19-9: Biochemical and Clinical Aspects. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-94-017-7215-0_15

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.